J 2011

Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy

PAVLÍK, Tomáš, Eva JANOUŠOVÁ, Zdeněk POSPÍŠIL, Jan MUŽÍK, Daniela ŽÁČKOVÁ et. al.

Basic information

Original name

Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy

Authors

PAVLÍK, Tomáš (203 Czech Republic, belonging to the institution), Eva JANOUŠOVÁ (203 Czech Republic, belonging to the institution), Zdeněk POSPÍŠIL (203 Czech Republic, belonging to the institution), Jan MUŽÍK (203 Czech Republic, belonging to the institution), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Hana KLAMOVÁ (203 Czech Republic), Petr CETKOVSKÝ (203 Czech Republic), Marek TRNĚNÝ (203 Czech Republic), Jiří MAYER (203 Czech Republic, belonging to the institution) and Ladislav DUŠEK (203 Czech Republic, guarantor, belonging to the institution)

Edition

BMC Medical Research Methodology, 2011, 1471-2288

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.668

RIV identification code

RIV/00216224:14110/11:00065561

Organization unit

Faculty of Medicine

UT WoS

000296968400001

Keywords in English

chronic myeloid leukaemia; treatment; statistical methods

Tags

Tags

International impact, Reviewed
Změněno: 31/1/2014 12:43, RNDr. Eva Koriťáková, Ph.D.

Abstract

V originále

The current situation in the treatment of chronic myeloid leukaemia (CML) presents a new challenge for attempts to measure the therapeutic results, as the CML patients can experience multiple leukaemia-free periods during the course of their treatment. Traditional measures of treatment efficacy such as leukaemia-free survival and cumulative incidence are unable to cope with multiple events in time, e.g. disease remissions or progressions, and as such are inappropriate for the efficacy assessment of the recent CML treatment. The results have shown a difference between the estimates of the current cumulative incidence function and the common cumulative incidence of leukaemia-free patients, as well as between the estimates of the current leukaemia-free survival and the common leukaemia-free survival. Regarding the currently available follow-up period, both differences have reached the maximum (12.8% and 20.8%, respectively) at 3 years after the start of follow-up.

Links

NS10621, research and development project
Name: Optimalizace vytěžování informací z klinických zdravotnických registrů NZIS
Investor: Ministry of Health of the CR